Latest research on Ezetimibe

Ezetimibe is an anti-hyperlipidemic medication which is used to lower cholesterol levels. Specifically, it appears to bind to a critical mediator of cholesterol absorption, the Niemann-Pick C1-Like 1 (NPC1L1) protein on the gastrointestinal tract epithelial cells as well as in hepatocytes.

Ezetimibe dosage

There were 2 subjects (2.7%) in the Ezetimibe 10 mg group (1 cataract and 1 abdominal pain) and 5 subjects (6.5%) in the placebo group (2 cases of angina—one prior to study participation and one after study completion; 1 accidental overdose, 1 ankle fracture, 1 spinal osteoarthritis) that reported serious AEs. [source, 2015]
Therefore, also in consideration of the safety profile of this fixed association, we decided to test it in type 2 diabetic, hypercholesterolemic patients who were intolerant to high-dosage statins as an add-on therapy to low-dose statin and as add-on therapy to Ezetimibe, or alone in patients intolerant to any dose of statins. [source, 2015]
Among the 45 individuals enrolled in the trial, 15 who were not being treated with hypolipidemic drugs on enrollment due to a recent diagnosis of hypercholesterolemia and statin intolerance served as controls; 15 were diagnosed with hypercholesterolemia and treated with Ezetimibe (10 mg/day) due to statin intolerance diagnosed in the previous year; 15 were taking low doses of statins due to a diagnosed intolerance to high-dosage statins. [source, 2015]
Ezetimibe is a cholesterol medication that is especially useful when it is considered as an add-on treatment to the administration of low-dose statins in patients in whom reduction of the statin dosage results in the disappearance of the typical symptoms of statin intolerance. [source, 2015]
In fact, it can be added to treatment with statins in individuals who can tolerate low doses of statins and can be added to Ezetimibe in statin-intolerant individuals to enhance the clinical efficacy of the latter. [source, 2015]
The administration of berberine, formulated with silymarin to reduce its intestinal P-gp–mediated extrusion,14 in both patients being treated with low-dose statin or Ezetimibe and patients not undergoing any cholesterol-lowering therapy, produces a significant effect on TC. [source, 2015]
The lack of a direct comparison between placebo and Berberol® in randomized, statin-intolerant subjects, the lack of a group treated with low-dose statin or Ezetimibe alone, the lack of a double-blind design, and the small number of participants made it impossible to arrive at definite considerations. [source, 2015]
In this study, ten healthy male subjects were enrolled per cohort and received a single oral dose of Simvastatin or Ezetimibe alone, followed by four 2-h IV doses of Mipomersen over an 8-day period, with Simvastatin or Ezetimibe being administered again with the last dose of Mipomersen. [source, 2015]
Combination therapy that includes a statin plus another lipid-lowering agent (eg, Ezetimibe, bile acid resins, or niacin) can achieve a considerable reduction in LDL-C levels, while also limiting the risk of dose-related adverse effects from statin therapy. [source, 2015]
These drugs include Rosuvastatin 20–40 mg, Atorvastatin 40–80 mg, simvastatin 80 mg daily, and the combination of a statin at a moderate or high dose with Ezetimibe, a bile acid sequestrant, or niacin. [source, 2015]